VR Logo

Assembly Biosciences Inc. (ASMB) download report


Healthcare | Biotechnology & Pharma Research

Assembly Biosciences Inc. (ASMB) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.

IPO Date: 17-Dec-2010

CEO, Pres & Director: Dr. John G. McHutchison A.O., FRACP, M.D.

Chief Operating Officer: Mr. Jason A. Okazaki

Listing: NASDAQ: ASMB

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.assemblybio.com

Key Facts

Market cap: $100.53 Mln

Revenue (TTM): $6.25 Mln

Earnings (TTM): $-125.75 Mln

Cash: $123.00 Mln

Total Debt: $5.70 Mln

Insider's Holding: 1.52%

Liquidity: Low

52 Week range: $1.32 - 3.94

Shares outstanding: 48,216,500

10 Years Aggregate:

  • CFO: $-411.25 Mln
  • EBITDA: $-575.59 Mln
  • Net Profit: $-563.90 Mln

Stock Performance

Time Period Assembly Biosciences (ASMB) S&P BSE Sensex S&P Small-Cap 600
YTD-9.44-8.99-19.23
1 month9.33-3.40-9.35
3 months-8.26-8.50-16.59
1 Year-46.040.89-17.36
3 Years-46.1210.415.90
5 Years-36.6411.435.77
10 Years-20.6611.779.78
As on 30-Jun-2022
Year Assembly Biosciences (ASMB) S&P Small-Cap 600 S&P BSE Sensex
2021-61.4925.2721.99
2020-70.439.5715.75
2019-9.5520.8614.38
2018-49.82-9.705.87
2017272.4311.7327.91
201661.7824.741.95
2015-4.45-3.36-5.03